Table 1. Patients’ characteristics categorized by gender, clinical stage, grading, and histology.
| Characteristics | CB1 gene (qRT-PCR) | CB2 gene (qRT-PCR) | CB1 protein (IHC) | CB2 protein (IHC) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pos./total (%) | P value | Pos./total (%) | P value | Pos./total (%) | P value | Pos./total (%) | P value | ||||
| Gender | |||||||||||
| Female | 4/31 (12.9%) | 0.503 | 26/31 (83.9%) | 0.656 | 11/26 (42.3%) | 0.756 | 6/27 (22.2%) | 0.295 | |||
| Male | 14/67 (20.9%) | 52/67 (77.6%) | 16/45 (35.6%) | 17/46 (37.0%) | |||||||
| Stage | |||||||||||
| IA | 9/31 (29.0%) | 0.369 | 29/31 (93.5%) | 0.047 | 12/22 (54.5%) | 0.028 | 5/22 (22.7%) | 0.779 | |||
| IB | 2/24 (8.3%) | 20/24 (83.3%) | 8/15 (53.3%) | 6/18 (33.3%) | |||||||
| IIA | 3/16 (18.8%) | 12/16 (75.0%) | 1/11 (9.1%) | 3/10 (30.0%) | |||||||
| IIB | 3/16 (18.8%) | 10/16 (62.5%) | 5/14 (35.7%) | 5/14 (35.7%) | |||||||
| IIIA | 1/11 (9.1%) | 7/11 (63.6%) | 1/9 (11.1%) | 4/9 (44.4%) | |||||||
| Grade | |||||||||||
| 1 | 1/5 (20.0%) | 0.739 | 5/5 (100.0%) | 0.286 | 2/2 (100.0%) | 0.023 | 0/2 (0.0%) | 1 | |||
| 2 | 7/32 (21.9%) | 27/32 (84.4%) | 12/23 (52.2%) | 7/22 (31.8%) | |||||||
| 3 | 9/57 (15.8%) | 42/57 (73.7%) | 12/43 (27.9%) | 14/46 (30.4%) | |||||||
| Histology | |||||||||||
| Adenocarcinoma | 7/40 (17.5%) | 0.24 | 34/40 (85.0%) | 0.147 | 15/31 (48.4%) | 0.288 | 12/32 (37.5%) | 0.171 | |||
| Large-cell carcinoma | 3/7 (42.9%) | 7/7 (100.0%) | 2/7 (28.6%) | 0/7 (0.0%) | |||||||
| Squamous-cell carcinoma | 8/51 (15.7%) | 37/51 (72.5%) | 10/33 (30.3%) | 11/34 (32.4%) | |||||||
Data are presented as n/N (%). CB1, cannabinoid receptor 1; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; pos., positive; CB2, cannabinoid receptor 2; IHC, immunohistochemistry.